MARKET

ACXP

ACXP

Acurx Pharmaceuticals Inc
NASDAQ
1.900
+0.030
+1.60%
Opening 09:32 11/08 EST
OPEN
1.850
PREV CLOSE
1.870
HIGH
1.900
LOW
1.850
VOLUME
2.45K
TURNOVER
--
52 WEEK HIGH
5.28
52 WEEK LOW
1.520
MARKET CAP
30.87M
P/E (TTM)
-1.6487
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACXP last week (1028-1101)?
Weekly Report · 4d ago
Weekly Report: what happened at ACXP last week (1021-1025)?
Weekly Report · 10/28 09:39
Acurx Ready To Expand Pipeline With Anthrax Treatment
Seeking Alpha · 10/21 14:07
Acurx’s ibezapostat shows favorable effect in Phase 2b CDI trial
TipRanks · 10/21 11:11
Acurx Pharmaceuticals Announced The Presentation Of A Scientific Poster At The Infectious Diseases Society Of America IDWeek 2024 Conference
Benzinga · 10/21 11:06
ACURX ANNOUNCES NEW BILE ACID AND MICROBIOME ANALYSES FROM PH2B TRIAL OF IBEZAPOLSTAT IN CDI PATIENTS PRESENTED AT IDWEEK SCIENTIFIC CONFERENCE
Reuters · 10/21 11:00
Weekly Report: what happened at ACXP last week (1014-1018)?
Weekly Report · 10/21 09:39
Weekly Report: what happened at ACXP last week (1007-1011)?
Weekly Report · 10/14 09:47
More
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.

Webull offers Acurx Pharmaceuticals Inc stock information, including NASDAQ: ACXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACXP stock methods without spending real money on the virtual paper trading platform.